172 related articles for article (PubMed ID: 7537519)
1. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
Freemantle SJ; Jackman AL; Kelland LR; Calvert AH; Lunec J
Br J Cancer; 1995 May; 71(5):925-30. PubMed ID: 7537519
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Dolnick BJ; Lu K; Yin MB; Rustum YM
Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
[TBL] [Abstract][Full Text] [Related]
5. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
6. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors.
Kobayashi H; Takemura Y; Miyachi H; Skelton L; Jackman AL
Jpn J Cancer Res; 1995 Nov; 86(11):1014-8. PubMed ID: 8567390
[TBL] [Abstract][Full Text] [Related]
7. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
8. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
9. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.
O'Connor BM; Jackman AL; Crossley PH; Freemantle SE; Lunec J; Calvert AH
Cancer Res; 1992 Mar; 52(5):1137-43. PubMed ID: 1737372
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
Aherne GW; Hardcastle A; Raynaud F; Jackman AL
Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Wang W; Marsh S; Cassidy J; McLeod HL
Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
[TBL] [Abstract][Full Text] [Related]
12. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
13. Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.
Horowitz RW; Zhang H; Schwartz EL; Ladner RD; Wadler S
Biochem Pharmacol; 1997 Sep; 54(5):635-8. PubMed ID: 9337081
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
15. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL
Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL
J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277
[TBL] [Abstract][Full Text] [Related]
18. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
Drake JC; Allegra CJ; Moran RG; Johnston PG
Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551
[TBL] [Abstract][Full Text] [Related]
19. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
20. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Kelland LR; Kimbell R; Hardcastle A; Aherne GW; Jackman AL
Eur J Cancer; 1995 Jun; 31A(6):981-6. PubMed ID: 7646933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
